
NICE Recommends Pembrolizumab for Advanced Lung Cancer Following Additional Price Cut
NICE recommends pembrolizumab for use in advanced lung cancer following additional data review and a further discount in price.
The National Institute for Health and Care Excellence (NICE), which advises the UK’s National Health Services (NHS) on coverage policies, has approved the use of Merck’s programmed death-1 inhibitor pembrolizumab (Keytruda) for use in adults with advanced lung cancer whose tumors express the programmed death ligand-1 protein.
In a previous version of the guidance
Carole Longson, who heads the NICE Centre for Health Technology Evaluation,
The current guidance states that patients will remain on the drug for 2 years and will stop subsequent treatment if their disease has not progressed.
Meanwhile, a competitor product by Bristol-Myers Squibb, nivolumab (Opdivo), remains off the NICE formulary for treatment of advanced lung cancer due to
Newsletter
Stay ahead of policy, cost, and value—subscribe to AJMC for expert insights at the intersection of clinical care and health economics.